key: cord-1048077-c0p1ilnp
authors: Priluck, Aaron Zachariah; Arevalo, Jose Fernando; Pandit, Ravi Rashmikant
title: Ischemic retinal events after COVID-19 vaccination
date: 2022-04-18
journal: Am J Ophthalmol Case Rep
DOI: 10.1016/j.ajoc.2022.101540
sha: e15fc29a469b870b04082e53740919f48d4dbce7
doc_id: 1048077
cord_uid: c0p1ilnp

PURPOSE: We report 2 cases of ischemic retinal events occurring soon after administration of the Moderna and Johnson & Johnson/Janssen COVID-19 vaccines. To our knowledge, these are the first reports of isolated ischemic retinal events occurring after COVID-19 vaccination. OBSERVATIONS: A 57-year-old female had new onset floaters of the left eye within days of her second Moderna COVID-19 vaccination, which progressively worsened prompting her to present for evaluation. She was diagnosed with a branch retinal vein occlusion in the left eye. A 20-year-old female presented with persistent central scotomata in both eyes, which she first noticed two days after her Johnson & Johnson/Jannsen COVID-19 vaccination. She was diagnosed with acute macular neuroretinopathy of both eyes. CONCLUSIONS: and Importance: The potential side effects of COVID-19 vaccines are still being established; however, there has been concern over pro-thrombotic events with these vaccines, with most concerns directed toward the Johnson & Johnson vaccine. We observed likely transient pro-thrombotic retinal milieu in patients who received these vaccines though it remains unclear whether there is a shared mechanism between systemic response to the COVID-19 spike protein and the highly pro-thrombotic state seen in COVID-19 infections. In the case of our patients, we postulate their immunologic responses to the vaccines – and possibly a resultant pro-thrombotic state – may have precipitated their ischemic retinal events. We thus recommend that patients with ocular symptoms after COVID-19 vaccination undergo comprehensive ophthalmologic evaluation.

On April 12, 2021, she received the second dose of the Moderna vaccine and had a fever 64 followed by the onset of floaters, which progressively worsened prompting evaluation three 65 weeks later. Her visual acuity was 20/20 in each eye; intraocular pressures were unremarkable; 66 there was no relative afferent pupillary defect; and her visual fields were full to confrontation. 67

Dilated examination of the right eye was unremarkable; dilated examination of the left eye 68 revealed a supero-temporal branch retinal vein occlusion (BRVO) with superficial intraretinal 69 J o u r n a l P r e -p r o o f hemorrhages scattered along the superior arcade without macular edema (Figure 1 ). Her blood 70 pressure at her most recent primary care visit was 124/77 mmHg. Observation was recommended 71

given absence of macular edema and preserved visual acuity. Macular edema developed and 72 visual acuity declined to 20/30 at two months after initial presentation for which she was treated 73 with intravitreal aflibercept monthly for 6 months. Visual acuity at most recent follow-up was 74 20/25, and OCT demonstrated persistent foveal-sparing macular edema; she did not receive a 75 booster vaccine. 76

A 20-year-old Caucasian female with a history of allergic rhinitis and myopia presented with 1 78

week of new, persistent central scotomata in both eyes ( temporarily halting use of the J&J vaccination. One day after vaccination, she developed 83 subjective fever, chills, myalgias, and headaches; symptoms responded well to oral ibuprofen. 84

The following day, she noted new central blind spots in both eyes. She discontinued her birth 85 control medication due to her concern for thrombosis. An MRI brain without contrast was 86 ordered by her primary care physician and was without acute abnormalities. The patient was diagnosed with acute macular neuroretinopathy (AMN) of both eyes, and further 107 history was obtained to identify other potential risk factors for the development of AMN. The 108 patient reported sparse caffeine use (1 cup of coffee every 2-3 days) but had self-discontinued 109 caffeine after researching her symptoms. She denied any recent infections, trauma, and 110 confirmed that she was not on any sympathomimetic agents. There was no family history of 111 autoimmunity or coagulopathy. IV safety data is collected. However, there has been concern over pro-thrombotic events with 162 these vaccines, with most concerns directed toward the J&J vaccine. 14-16 Numerous cases of 163 AMN and retinal vein occlusion possibly related to recent COVID-19 vaccination have been 164 reported since our initial observations, though the majority of these reports pertain to the Pfizer 165 and AstraZeneca vaccinessee Tables 1 and 2 

Prevention CfDCa. CDC Recommends Use of Johnson & Johnson's Janssen

Prevention CfDCa. Data from: The Vaccine Adverse Event Reporting System (VAERS)

The epidemiology of retinal vein occlusion: the 199

Branch retinal vein occlusion: epidemiology, 201 pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the 202 literature. Retina

Paracentral acute middle maculopathy spectral-domain optical 204 coherence tomography feature of deep capillary ischemia

Acute macular neuroretinopathy: A comprehensive 207 review of the literature

Optical Coherence Tomography Angiography of Acute 210

RETINAL MICROVASCULATURE ALTERATION IN 213 PARACENTRAL ACUTE MIDDLE MACULOPATHY AND ACUTE MACULAR NEURORETINOPATHY: A 214 QUANTITATIVE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY STUDY. Retin Cases Brief 215 Rep

Projection-Resolved OCT Angiography 217 of Microvascular Changes in Paracentral Acute Middle Maculopathy and Acute Macular 218

Microvascular change in acute macular neuroretinopathy by using 221 optical coherence tomography angiography

Assessing Deep Retinal Capillary Ischemia in 224

Paracentral Acute Middle Maculopathy by Optical Coherence Tomography Angiography

Acute Macular Neuroretinopathy Following the 227 Administration of an Influenza Vaccination

Updated Recommendations from the Advisory 230

Committee on Immunization Practices for Use of the Janssen

Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine 232

Recipients -United States

Characterizing the incidence of adverse events of 235 special interest for COVID-19 vaccines across eight countries: a multinational network cohort 236 study. medRxiv

US Case Reports of Cerebral Venous Sinus Thrombosis With 238

Thrombocytopenia After Ad26.COV2.S Vaccination

Acute macular neuroretinopathy 241 following Pfizer-BioNTech COVID-19 vaccination

Acute macular neuroretinopathy 244 (AMN) following COVID-19 vaccination

Retinal Vascular Events after mRNA and 247

Adenoviral-Vectored COVID-19 Vaccines-A Case Series

ACUTE MACULAR NEURORETINOPATHY AFTER COVID-19 250 VACCINATION. Retin Cases Brief Rep

ACUTE MACULAR NEURORETINOPATHY AFTER SARS-COV-2 253 VACCINATION. Retin Cases Brief Rep

Bilateral acute macular neuroretinopathy in 256 a young woman after the first dose of Oxford-AstraZeneca COVID-19 vaccine

Two Cases of Acute Macular Neuroretinopathy 259 Associated with the Adenovirus-based COVID-19 Vaccine Vaxzevria (Astrazeneca)

Acute macular neuroretinopathy 262 following COVID-19 vaccination. Eye (Lond)

Acute Macular 264 Neuroretinopathy following Coronavirus Disease 2019 Vaccination

Central retinal vein occlusion occurring 270 immediately after 2nd dose of mRNA SARS-CoV-2 vaccine

Retinal Hemorrhage after SARS-CoV

Retinal Vein Occlusion Following Two Doses 275 of mRNA-1237 (Moderna) Immunization for SARS-Cov-2: A Case Report. Ophthalmol Ther

Central retinal vein occlusion after mRNA 278 SARS-CoV-2 vaccination: A case report

Combined central 281 retinal artery and vein occlusion shortly after mRNA-SARS-CoV-2 vaccination

Central retinal vein occlusion post-COVID-19 284 vaccination

Retinal vein occlusion following COVID-286 19 vaccination

We believe these individuals should be listed as authors because:[Please elaborate below] X We confirm that the manuscript has been read and approved by all named authors.We confirm that the order of authors listed in the manuscript has been approved by all named authors.

The Corresponding Author declared on the title page of the manuscript is:

X This author submitted this manuscript using his/her account in EVISE.X We understand that this Corresponding Author is the sole contact for the Editorial process (including EVISE and direct communications with the office). He/she is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs.X We confirm that the email address shown below is accessible by the Corresponding Author, is the address to which Corresponding Author's EVISE account is linked, and has been configured to accept email from the editorial office of American Journal of Ophthalmology Case Reports:

Someone other than the Corresponding Author declared above submitted this manuscript from his/her account in EVISE:

X We understand that this author is the sole contact for the Editorial process J o u r n a l P r e -p r o o f 4 (including EVISE and direct communications with the office). He/she is responsible for communicating with the other authors, including the Corresponding Author, about progress, submissions of revisions and final approval of proofs.We the undersigned agree with all of the above.Author's name (Fist, Last) Signature Date